TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

Search

CSL Ltd

Fechado

SetorSetor Industrial

257.01 0.65

Visão Geral

Variação de preço das ações

24h

Atual

Mín

250.43

Máximo

257.24

Indicadores-chave

By Trading Economics

Rendimento

1.3B

2B

Vendas

1.5B

8.2B

P/E

Médio do Setor

28.972

33.198

EPS

1.831

Rendimento de Dividendos

1.7

Margem de lucro

24.437

Funcionários

32,698

EBITDA

1.5B

3.2B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+26.05% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.70%

2.54%

Próxima data de dividendos

9 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-14B

121B

Abertura anterior

256.36

Fecho anterior

257.01

Sentimento de Notícias

By Acuity

34%

66%

121 / 468 Ranking em Industrials

CSL Ltd Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de fev. de 2025, 21:55 UTC

Ganhos

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 de fev. de 2025, 21:34 UTC

Ganhos

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

12 de ago. de 2024, 23:23 UTC

Ganhos

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12 de ago. de 2024, 22:49 UTC

Ganhos

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

21 de mar. de 2025, 02:03 UTC

Conversa de Mercado

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 de fev. de 2025, 22:30 UTC

Conversa de Mercado

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 de fev. de 2025, 21:40 UTC

Ganhos

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 de fev. de 2025, 21:19 UTC

Ganhos

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 de fev. de 2025, 21:13 UTC

Ganhos

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 de fev. de 2025, 21:12 UTC

Ganhos

CSL Interim Dividend US$1.30/Security

10 de fev. de 2025, 21:12 UTC

Ganhos

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10 de fev. de 2025, 21:11 UTC

Ganhos

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7 de nov. de 2024, 03:53 UTC

Conversa de Mercado

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22 de out. de 2024, 22:53 UTC

Conversa de Mercado

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10 de out. de 2024, 22:20 UTC

Conversa de Mercado

CSL Bull Looking for Update on Gross Margin -- Market Talk

13 de ago. de 2024, 00:33 UTC

Conversa de Mercado

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12 de ago. de 2024, 22:34 UTC

Ganhos

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12 de ago. de 2024, 22:18 UTC

Ganhos

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12 de ago. de 2024, 22:18 UTC

Ganhos

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12 de ago. de 2024, 22:17 UTC

Ganhos

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12 de ago. de 2024, 22:16 UTC

Ganhos

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12 de ago. de 2024, 22:15 UTC

Ganhos

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12 de ago. de 2024, 22:14 UTC

Ganhos

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12 de ago. de 2024, 22:13 UTC

Ganhos

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12 de ago. de 2024, 22:13 UTC

Ganhos

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12 de ago. de 2024, 22:11 UTC

Ganhos

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12 de ago. de 2024, 22:10 UTC

Ganhos

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12 de ago. de 2024, 22:09 UTC

Ganhos

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12 de ago. de 2024, 22:08 UTC

Ganhos

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12 de ago. de 2024, 22:07 UTC

Ganhos

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

Comparação entre Pares

Variação de preço

CSL Ltd Previsão

Preço-alvo

By TipRanks

26.05% parte superior

Previsão para 12 meses

Média 317.092 AUD  26.05%

Máximo 360.3 AUD

Mínimo 250 AUD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para CSL Ltd - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

12

Comprar

2

Manter

0

Vender

Sentimento

By Acuity

121 / 468 Ranking em Setor Industrial

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.